Media Requests
Please send all media-related inquiries and interview requests to mediarelations@lls.org.
An LLS representative will respond as soon as possible.
Aptose Biosciences Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML Research Initiative With Oregon Health & Science University
Contact:
Andrea Greif, Senior Director of Communications
The Leukemia & Lymphoma Society
914-821-8958
andrea.greif@lls.org
SAN DIEGO, CALIFORNIA and TORONTO, CANADA; PORTLAND, OREGON; WHITE PLAINS, NEW YORK - September 29, 2014 - Aptose Biosciences Inc. (TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechan...
Louis J. DeGennaro, Ph.D., Named President and Chief Executive Officer of The Leukemia & Lymphoma Society
Contact: Andrea Greif
(914) 821-8958
andrea.greif@lls.org
White Plains, NY (September 9, 2014) - The Leukemia & Lymphoma Society (LLS) announced today that Louis J. DeGennaro, Ph.D., has been appointed as president and chief executive officer, effective immediately.
"Dr. DeGennaro has tirelessly dedicated himself for almost a decade of service to the LLS mission and to the patients whom w...
The Leukemia & Lymphoma Society Provides Equity Financing to OncoPep to Support Clinical Trial for Myeloma Vaccine
Contact: Andrea Greif
(914) 821-8958
andrea.greif@lls.org
White Plains, NY (Aug. 28, 2014) - The Leukemia & Lymphoma Society (LLS) and OncoPep have entered a partnership to advance an experimental cancer vaccine to treat patients with smoldering multiple myeloma (SMM), an asymptomatic stage of myeloma.
The partnership is through LLS's Therapy Acceleration Program® (TAP), through which LL...
Five Things You Need To Know About Blood Cancers And One Thing You Can Do
Contact: Marcie Klein
(914) 821-8205
marcie.klein@lls.org
White Plains, NY (August 27, 2014) - Every three minutes, someone in the U.S. is diagnosed. More than 1.1 million Americans are living with, or in remission from, these diseases. Certain forms of these diseases are the most common types of cancer in children and adolescents younger than 20 years. Almost 150,000 Americans will be dia...
The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers
(White Plains, NY) - July 23, 2014 - Today's U.S. Food and Drug Administration (FDA) approval of idelalisib to treat patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) is a significant advance for patients with these blood cancers.
Idelalisib, which goes by the trade name Zydelig (R), is a first-in-class inhibi...
Record-Breaking Year for the Leukemia & Lymphoma Society's Man & Woman of the Year Campaign
Contact: Kristin Hoose
(914) 821-8973
kristin.hoose@lls.org
White Plains, NY (July 17, 2014) - A Chicago man and Los Angeles woman raised $386,284 and $343,962, respectively, to support The Leukemia & Lymphoma Society's (LLS) mission to find cures for blood cancers and ensure that patients have access to lifesaving treatments. As the leading fundraisers in the 2014 Man & Woman of t...
James Davis, Biotechnology Consultant, Elected Chair of LLS National Board of Directors
For Immediate Release
Contact: Andrea Greif
Tel: (914) 821-8958
Cell: (914) 772-3027
andrea.greif@lls.org
News Release
White Plains, N.Y. (July 16, 2014) - James Davis, Ph.D., JD, a consultant in crisis management and the launch of new technologies for biotechnology and other companies, has been elected chairman of the national board of directors of The Leukemia & Lymphoma...
Burlington and The Leukemia & Lymphoma Society: Saving Lives is Always in Style
White Plains, NY (July 14, 2014) - Burlington and The Leukemia & Lymphoma Society's (LLS) Light The Night® Walk fundraising campaign have partnered once again to raise money for blood cancer research. Burlington, the #1 National Corporate Light The Night partner, launches its 13th consecutive company-wide initiative today by encouraging its customers to make a donation at checkout to benefit LLS. As p...